Nucleoside analogue delivery systems in cancer therapy

Expert Opinion on Drug Delivery

Volumn 4, Issue 5, 2007, Pages 513-531

  Diab, Roudayna ^a   Degobert, Ghania ^a   Hamoudeh, Misara ^a   Dumonter, Charles ^b   Fesssi, Hatem ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Dendrimers; DepoFoam ; Inclusion complexes; Liposomes; Microparticles; Nanoparticles; Particles; Polymeric micelles; Polyplex nanogels; Stealth ; Vesicular phospholipid gel

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZIDODEOXYTHYMIDINE TRIPHOSPHATE; BIOMATERIAL; CLADRIBINE; CLOFARABINE; CYCLODEXTRIN; CYTARABINE; CYTOTOXIC AGENT; DENDRIMER; DRUG CARRIER; EUDRAGIT; FLUDARABINE; FLUOROURACIL; GEMCITABINE; MACROGOL; NANOPARTICLE; NUCLEOSIDE ANALOG; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; POLYAMIDE; POLYAMIDOAMINE; POLYANHYDRIDE; POLYETHYLENEIMINE; POLYLACTIDE; POLYSTYRENE; PRODRUG; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CATABOLISM; COMPLEX FORMATION; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENCAPSULATION; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HUMAN; HYDROGEL; HYDROPHILICITY; LEUKOPENIA; LIVER TOXICITY; MEMBRANE PERMEABILITY; MICELLE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PERICARDITIS; PHOSPHORYLATION; REVIEW; THROMBOCYTOPENIA;

EID: 34948876504     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.5.513     Document Type: Review

References (73)

1. GALMARINI CM, MACKEY JR, DUMONTET C: Nucleosides analogues and nucleobases in cancer treatment. Lancet Oncol. (2002) 3:415-424.
2. HUNSUCKER SA, MITCHELL BS, SPYCHALA J: The 5′-nucleotidases as regulators of nucleotides and drug metabolism. Pharmacol. Ther. (2005) 107:1-30.
3. MANGRAVITE LM, BADAGNANI I, GIACOMINI KM: Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur. J. Pharmacol. (2003) 479:269-281.
4. VAN ROMPY AR, JOHANSSON M, KARLSSON A: Substrate specificity and phosphorylation of antiviral and anticancer nucleosides analogues by human deoxyribonucleoside kinanses and ribonucleoside kinases. Pharmacol. Ther. (2003) 100:119-139.
5. SONG X, LORENZI PL, LANDOWSKI CP, VIG BS: Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol. Pharm. (2005) 2(2):157-167.
6. MANSSON E, FLORDAL E, LILIEMARK et al.: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotides reductases activity contributes to fludarabine resistance. Biochem. Pharmacol. (2003) 65:237-247.
7. SÈVE P, MACKEY JR, ISAAC S et al.: CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 49:363-370.
8. GALMARINI CM, THOMAS X, CALVO F et al.: Potential mechanisms of resistance to cytarabine in AML patients. Leuk. Res. (2002) 26:621-629.
9. GENINI D, ADACHI S, CHAO Q et al.: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood (2000) 96( 10):3537-3543.
10. SHIPLEY LA, BROWN TJ, CORNPROPST JD et al.: Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos. (1992) 20(6):849-855.
11. HALE JT, BIGELOW JC, MATHEWS LA et al.: Analytical and pharmacokinetic studies with 5-chloro-2′-deoxycytidine. Biochem. Pharmacol. (2002) 64:1493-1502.
12. LINDEMALM S, LILIEMARK J, GUNNAR J et al.: Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukaemia. Cancer Lett. (2004) 210:171-177.
13. MASSING U, FUXIUS S: Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resist. Update (2000) 3:171-177.
14. HOFHEINZ R, GNAD-VOGT SU, BEYER U et al.: Liposomal encapsulated anti-cancer drugs. Anticancer Drugs (2005) 16:691-707.
15. DRUMMOND DC, KIRPOTIN D, BENZ CC et al.: Liposomal drug delivery systems for cancer therapy. In: Cancer Drug Discovery and Development. Drug Delivery Systems in Cancer Therapy. Brown DM (Ed.), Humans Press, Inc., New Jersey (2004):191-213.
16. MAYER LD, KRISHNA R., BALLY MB: Liposomes for cancer therapy applications. In: Polymeric Biomaterials, 2nd Edition. DUMITRIU S (Ed.), Marcel Dekker, New York, NY (2001):823-841.
17. FUNATO K, YODA R, KIWADA H: Contribution of complement system on destabilization of liposomes of hydrogenated egg phosphatidylcholine in fresh rat plasma. Biochim. Biophys. Acta (1992) 1103:198-204.
18. PATEL HM: Serum opsonins and liposomes: their interaction opsonophagocytosis. Crit. Rev. Ther. Drug (1992) 9:39-90.
19. SUBRAMANIAN N, YAJNIK A, MURTHY RS: Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes. AAPS Pharm. Sci. Tech. (2004) 5(1):E4.
20. CELANO M, CALVAGNO MG, BULOTTA S et al.: Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer (2004) 4:63.
21. HAMADA A, KAWAGUCHI T, NAKANO M: Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. (2002) 41(10):705-718.
22. ANDERSEN TL, JENSEN SS, JØRGENSEN K: Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog. Lipid Res. (2005) 44:68-97.
23. MANTRIPRAGADA SB, HOWELL SB: Sustained-release drug delivery with DepoFoam. In: Cancer Drug Discovery and Development. Drug Delivery Systems in Cancer Therapy. Brown DM (Ed.), Humana Press, Inc., New Jersey (2004):247-262.
24. JAIN SK, JAIN RK, CHOURASIA MK et al.: Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium. AAPS Pharm. Sci. Tech. (2005) 6(1):E35.
25. BRANDL M, BACHMANN D, DRECHSLER M et al.: Liposome preparation using high-pressure homogenizers. In: Liposome Technology. 2nd Edition. Gregoriadis G (Ed.), CRC (1993) 1:49-65.
26. BRANDL M, DRECHSLER M, BACHMANN D et al.: Morphology of semisolid aqueous phosphatidylcholine dispersions, a freeze fracture electron microscopy study. Chem. Phys. Lipids (1997A) 87:65-72.
27. MOOG R, BURGER AM, BRANDL M et al.: Change in pharmacokinetic and pharmacodynamic behaviour of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother. Pharmacol. (2002) 49:356-366.
28. KAISER N, KIMPFLER A, MASSING U et al.: 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int. J. Pharm. (2003) 256:123-131.
29. HUWANG S, BAEK N, PARK H et al.: Hydrogels in cancer drug delivery systems. In: Cancer Drug Discovery and Development. Drug Delivery Systems in Cancer Therapy. Brown DM (Ed.), Humana Press, Inc., New Jersey (2004):97-115.
30. GARCIA O, BLANCO MD, MARTIN JA et al.: 5-Fluorouracil trapping in poly (2-hydroxyethyl methacrylate-coacrylamide) hydrogels: in vitro drug delivery studies. Eur. Polym. J. (2000) 36:111-122.
31. ZHANG S, XU Y, WANG B et al.: Cationic compounds used in lipoplexes and polyplexes for gene delivery. J. Control. Rel. (2004) 100:165-180.
32. VINOGRADOV SV, ZEMAN AD, BATRAKOVA EV et al.: Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Rel. (2005) 107:143-157.
33. VINOGRADOV SV, KHOLI E, ZEMAN AD: Cross-linked polymeric nanogel formulations of 5′-triphosphates of nucleoside analogues: role of the cellular membrane in drug release. Mol. Pharm. (2005) 2(6):449-461.
34. TICE TR, MASON DW, GILLEY RM: Clinical use and future of parenteral microsphere delivery systems. In: Novel Drug Delivery and its Therapeutic Application. Prescott LF and Nimmo WS (Eds), John Wiley & Sons, New York, NY (1989):223-235.
35. MUVAFFAK A, GÜRHAN I, HASIRCI N: Cytotoxicity of 5-fluorouracil entrapped in gelatine microspheres. J. Microencapsul. (2004) 21(3):293-306.
36. GÖMEZ C, BLANCO MD, BERNARDO MV et al.: Cytarabine release from comatrices of albumin microspheres in a poly(lactide-co-glycolide) film: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. (2004) 57(2):225-233.
37. BLANCO MD, GÖMEZ C, OLMO R et al.: Chitosan microspheres in PLG films as devices for cytarabine release. Int. J. Pharm. (2000) 202:29-39.
38. RAHMAN Z, KHOLI R, KHAR RK et al.: Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS Pharm. Sci. Tech. (2006) 7(2):E47.
39. CIFTCI K, HINCAL AA, KAS HS et al.: Solid tumor chemotherapy and in vivo distribution of fluorouracil following administration in poly(L-lactic acid) microspheres. Pharm. Dev. Technol. (1997) 2:151-160.
40. BRINBAUM DT, BRANNON-PEPPAS L: Microparticle drug delivery systems. In: Cancer Drug Discovery and Development. Drug Delivery Systems in Cancer Therapy. Brown DM (Ed.), Humans Press, Inc., New Jersey (2004):117-135.
41. HITZMAN CJ, ELMQUIST WF, WATTENBERG LW, WIEDMANN TS: Development of a respirable, sustained release microcarrier for 5-fluorouracil: in vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J. Pharm. Sci. (2006) 95(5):1114-1126.
42. PEYMAN GA, CONWAY M, KHOOBEHI B, SOIKE K: Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. (1992) 16:109-113.
43. FOURNIER E, PASSIRANI C, COLIN N, BRETON P, SAGODIRA S, BENOIT JP: Development of novel 5-FU-loaded poly(methylidene malonare 2.1.2.)-based microspheres for the treatment of brain cancers. Eur. J. Pharm. Biopharm. (2004) 57:189-197.
44. LAMPRECHT A, YAMAMOTO H, TAKEUCHI H, KAWASHIMA Y: Microsphere design for the colonic delivery of 5-fluorouracil. J. Control. Rel. (2003) 90:313-322.
45. DAVIS SS: Biomedical applications of nanotechnology - implications for drug targeting and gene therapy. Trends Biotechnol. (1997) 15:217-224.
46. KAWASAKI ES, PLAYER A: Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. Nanomedicine (2005) 1:101-109.
47. LIU Y, MIYOSHI H, NAKAMURA M: Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer (2007) 120(12):2527-2537.
48. SLOMKOWSKI S: Biodegradable nano- and microparticles as carriers of bioactive compounds. Acta Pol. Pharm. (2006) 63(5):351-358.
49. BOZKIR A, SAKA OM: Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. Il Farmaco (2005) 60:840-846.
50. DEMBRI A, MONTISCI M, GANTIER JC, CHACUN H, PONCHEL J: Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. (2001) 18(4):467-473.
51. KUO Y: Loading efficiency of stavudine on polybutylcyanoacrylate and methyl methacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. (2005) 290:161-172.
52. YANG J, LEE H, HYUNG W, PARK SB, HAAM S: Magnetic PECA nanoparticles as drug carriers for targeted delivery: synthesis and release characteristics. J. Microencapsul. (2006) 23(2):203-212.
53. YANG J, PARK SB, YOON HG, HUH YM, HAAM S: Preparation of poly -̇caprolactone nanoparticles containing magnetite for magnetic drug carrier. Int. J. Pharm. (2006) 324:185-190.
54. LIU L, JIN P, CHENG M, ZHANG G, ZHANG F: 5-Fluorouracil-loaded self-assembled pH-sensitive nanoparticles as novel drug carrier for treatment of malignant tumors. Chinese J. Chem. Eng. (2006) 14(3):377-382.
55. GILLIES ER, FRÉCHET JMJ: Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today (2005) 10(1):35-43.
56. SVENSON S, TOMALIA DA: Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. (2005) 57:2106-2129.
57. KUKOWSKA-LATALLO JF, CANDIDO KA, CAO Z et al.: Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithehial cancer. Cancer Res. (2005) 65(12):5317-5324.
58. ZHUO RX, DU B, LU ZR: In vitro release of 5-fluorouracil with cyclic core dendritic polymer. J. Control. Rel. (1999) 57:249-257.
59. BHADRA D, BHADRA S, JAIN S, JAIN NK: A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. (2003) 257:111-124.
60. SCHIAVON O, PASUT G, MORO S, ORSOLINI P, GUIOTTO A, VERONESE FM: PEG-Ara-C conjugates for controlled release. Eur. J. Med. Chem. (2004) 39:123-133.
61. CHOE YH, CONOVER CD, WU D et al.: Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control. Rel. (2002) 79:55-70.
62. TORCHLLIN VP: Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. (2007) 24(1):1-16.
63. ZHOU JJ, CHEN RF, TANG QB, ZHOU QB, LU HW, WANG J: Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2. Chinese J. Cancer (2006) 25(12):1459-1463.
64. JIE P, VENKATRAMAN SS, MIN F, FREDDY BY, HUAT GL: Micelle-like nanoparticles of star-branched PEO-PLA copolymers as chemotherapeutic carrier. J. Control. Rel. (2005) 110:20-33.
65. MARTIN DEL VALLE EM: Cyclodextrins and their uses: a review. Process Biochem. (2004) 39:1033-1046.
66. WEN JQ, CUI W: Studies on the composition and stability constant of inclusion complexes of β-cyclodextrin with fluorouracil and ftorafur by NMR. Acta Pharm. Sin. (1990) 25(5):345-348.
67. BAHADDI Y, LELIÉVRE F, GAREIL P, MAIGNAN J, GALONS H: Preparation and complexation ability of zwitterionic derivatives of cyclodextrins. Carbohyd. Res. (1997) 303:229-232.
68. JORDHEIM L, DEGOBERT G, FESSI H et al.: Solubilization of a nucleotide analogue prodrug by hydroxypropyl-β-cyclodextrin. Proceedings of the 12th International Cyclodextrin Symposium, Montpellier (2004):291-294.
69. HILLAIREAU H, LE DOAN T, CHACUN H, JANIN J, COUVREUR P: Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. Int. J. Pharm. (2007) 331:148-152.
70. PORT RE, SCHUSTER C, PORT CR, BACHERT P: Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging. Cancer Chemother. Pharmacol. (2006) 58(5):607-617.
71. MOOG R, BURGER AM, BRANDL M et al.: Change in pharmacokinetic and pharmacodynamic behaviour of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. Cancer Chemother. Pharmacol. (2002) 49(5):356-366.
72. KAISER N, KIMPFLER A, MASSING U et al.: 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int. J. Pharm. (2003) 256:123-131.
73. MANTRIPRAGADA S: A lipid based depot (DepoFoam1 technology) for sustained release drug delivery. Prog. Lipid Res. (2002) 41: 392-406.